Molecular diagnostics revenues rose 5 percent driven in part by growth in infectious disease testing, a core area of diagnostic market focus for the firm.
The investment bank expects Abbott's Diagnostic division to grow in the mid-single digits driven in part by global launches of its Alinity systems.
The firm is developing tests combining biomarkers and other clinical measures to diagnose and monitor patients and identify those at risk of long-term effects.
Becton Dickinson got clearance for a platform and test for the rapid identification and determination of antimicrobial susceptibility of gram-negative bacteria.
The test uses the same blood draw of a routine health exam and was designed to be unaffected biotin, a vitamin supplement that may skew some lab test results.
Qiagen's partnership and merger agreement with NeuMoDx may help it compete with high-volume molecular testing vendors such as Abbott, Hologic, and Roche.
Siemens Healthineers received FDA clearances for several assays, including separate allowances for tests using hemoglobin A1c, troponin I, and procalcitonin biomarkers.
The company was encouraged by the clinical use of the existing handheld instrument in hospitals and soon plans to launch it with a broader menu, it said at AACC.
Abbott confirmed that the move is a consequence of TwistDx evaluating its operations and strategic direction to align operations and commercial needs.